Innoviva Inc Total Liabilities
Innoviva Inc total liabilities. Based on the latest financial reports, Innoviva Inc (INVA) has total liabilities worth $469.46 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Innoviva Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Innoviva Inc (2000–2025)
Total liabilities of Innoviva Inc from 2000 to 2025. This chart illustrates how Innoviva Inc's total liabilities have evolved over time, based on quarterly financial data. Explore INVA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Innoviva Inc Competitors by Total Liabilities
The table below lists competitors of Innoviva Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alkane Resources Ltd
AU:ALK
|
Australia | AU$382.43 Million |
|
Bank of Qingdao Co. Ltd
F:4BQ
|
Germany | €764.71 Billion |
|
Kimbell Royalty Partners LP
NYSE:KRP
|
USA | $497.49 Million |
|
Jiamei Food Packaging Chuzhou Co
SHE:002969
|
China | CN¥1.13 Billion |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
USA | $463.81 Million |
|
Kuaijishan Shaoxing Rice Wine
SHG:601579
|
China | CN¥871.54 Million |
|
Mota-Engil SGPS S.A
LS:EGL
|
Portugal | €8.27 Billion |
|
Nyfosa AB (publ)
ST:NYF
|
Sweden | Skr26.07 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Innoviva Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Innoviva Inc balance sheet assets.
Liquidity & Leverage Metrics
Innoviva Inc Total Liabilities Ratios Explained
Innoviva Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innoviva Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innoviva Inc (2000–2025)
The table below shows the annual total liabilities of Innoviva Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $462.32 Million | -24.20% |
| 2024-12-31 | $609.90 Million | +7.27% |
| 2023-12-31 | $568.55 Million | -14.59% |
| 2022-12-31 | $665.71 Million | +66.24% |
| 2021-12-31 | $400.46 Million | +2.23% |
| 2020-12-31 | $391.73 Million | +2.36% |
| 2019-12-31 | $382.71 Million | -1.65% |
| 2018-12-31 | $389.14 Million | -36.21% |
| 2017-12-31 | $610.04 Million | -16.66% |
| 2016-12-31 | $731.99 Million | -2.61% |
| 2015-12-31 | $751.58 Million | +0.88% |
| 2014-12-31 | $745.00 Million | +94.96% |
| 2013-12-31 | $382.13 Million | +78.94% |
| 2012-12-31 | $213.55 Million | -38.25% |
| 2011-12-31 | $345.83 Million | -2.20% |
| 2010-12-31 | $353.62 Million | -4.53% |
| 2009-12-31 | $370.39 Million | -0.19% |
| 2008-12-31 | $371.11 Million | +62.59% |
| 2007-12-31 | $228.25 Million | +14.63% |
| 2006-12-31 | $199.11 Million | +20.49% |
| 2005-12-31 | $165.25 Million | +72.76% |
| 2004-12-31 | $95.66 Million | -77.49% |
| 2003-12-31 | $425.01 Million | +0.09% |
| 2002-12-31 | $424.65 Million | +1773.59% |
| 2000-12-31 | $22.66 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more